RP 5063

Drug Profile

RP 5063

Alternative Names: RP 5000; RP5063

Latest Information Update: 21 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Reviva Pharmaceuticals
  • Class Antipsychotics; Small molecules
  • Mechanism of Action Dopamine D2 receptor partial agonists; Dopamine D3 receptor partial agonists; Dopamine D4 receptor partial agonists; Serotonin 1A receptor partial agonists; Serotonin 2A receptor partial agonists; Serotonin 2B receptor antagonists; Serotonin 6 receptor antagonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Schizoaffective disorder; Schizophrenia
  • Phase I Attention-deficit hyperactivity disorder; Bipolar disorders; Major depressive disorder; Psychotic disorders
  • Preclinical Autistic disorder; Gilles de la Tourette's syndrome; Pulmonary arterial hypertension

Most Recent Events

  • 17 Oct 2017 Reviva Pharmaceuticals plans to initiate a phase II trial for Pulmonary arterial hypertension in early 2018
  • 17 Nov 2016 RP 5063 receives Orphan Drug status for Pulmonary arterial hypertension in USA
  • 19 May 2016 Preclinical trials in Pulmonary arterial hypertension in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top